Biomark Med . Usefulness of C-reactive protein/albumin ratio as a predictor of new-onset atrial fibrillation in SARS coronavirus-2

[tetano]

Biomark Med


. 2021 Aug 18.
doi: 10.2217/bmm-2020-0866. Online ahead of print.
Usefulness of C-reactive protein/albumin ratio as a predictor of new-onset atrial fibrillation in SARS coronavirus-2


Saban Kelesoglu ¹ , Yucel Yilmaz ² , Eyup Ozkan ² , Bekir Calapkorur ² , Zehra B Dursun ³ , Aysegul Ulu-Kilic ⁴ , Deniz Elcık ¹



Affiliations

• PMID: 34406031
• DOI: 10.2217/bmm-2020-0866

Abstract

Aim: To investigate whether C-reactive protein/albumin ratio (CAR) has an association with new onset atrial fibrillation (NOAF) in SARS-CoV-2. Materials & methods: This study included 782 patients with SARS-CoV-2 infection, who were hospitalized in Turkey. The end point of the study was an occurrence of NOAF. Results: NOAF was identified in 41 patients (5.2%). Subjects who developed NOAF had a higher CAR compared with those who did not develop NOAF (p < 0.001). In the multivariate logistic regression analysis the CAR (odds ratio = 2.879; 95% CI: 1.063-7.793; p = 0.037) was an independent predictor of NOAF. Conclusion: A high level of CAR in blood samples is associated with an increased risk of developing NOAF in SARS-CoV-2.

Keywords: C-reactive protein/albumin ratio; SARS-CoV-2; new-onset atrial fibrillation.